CD276 and breast carcinoma: Anti-CD276 antibodies have the potential to selectively target many solid tumors, including most, if not all, breast cancers regardless of disease subtype and stage.14 However, the potent activity of ADCs has, to date, been severely hindered by target-antigen-independent toxicities driven by various factors.